About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 10726 record(s)
Req # A-2019-001346
Adverse Reaction Report (AER) for DEXILANT. Report numbers: 00726253, 000726460, 000726475, 000726674, 000726980, 000727460, E2B_02491366, E2B_02538249, E2B_02559280, E2B_02564898, E2B_02589953, E2B_02615425, E2B_02666199, E2B_02667689, E2B_02704921.Organization: Health Canada
January 2020
Req # A-2019-001347
Adverse Reaction Report (AER) for ENTYVIO. Report numbers: 725183, 725228, 726090, 728081, 728846, E2B_02440933, E2B_02449094, E2B_02450339, E2B_02467744, E2B_02476106, E2B_02506659, E2B_02510234, E2B_02514247, E2B_02516806, E2B_02523318, E2B_02534336, E2B_02534349, E2B_02541604, E2B_02541629, E2B_02542787, E2B_02605385, E2B_02610714, E2B_02615676, E2B_02622660, E2B_02674355, E2B_02680990, E2B_02563711, E2B_02713568, E2B_02552681, E2B_02570057, E2B_02575251, E2B_02568224.Organization: Health Canada
January 2020
Req # A-2019-001416
Adverse Reaction Report (AER). Report numbers: 000668591, E2B_02060970, E2B_02031121, E2B_01054239, E2B_02068338, E2B_02068345 E2B_0l661674, E2B_02133750, E2B_02695701, E2B_02262257, E2B_02281763, E2B_01120025, E2B_02262720.Organization: Health Canada
January 2020
Req # A-2019-001439
Adverse Reaction Report (AER) for botulinum toxin type A. Report number: E2B_02666592.Organization: Health Canada
January 2020
Req # A-2019-001447
Adverse Reaction Report (AER). Report numbers: E2B_02682751, E2B_02689623, E2B_02697016, E2B_02697020.Organization: Health Canada
January 2020
Req # A-2019-001451
Adverse Reaction Report (AER). Report numbers: E2B_02677393, E2B_02680918, E2B_02680919, E2B_02686684.Organization: Health Canada
January 2020
Req # A-2019-001452
Adverse Reaction Report (AER). Report numbers: 000728695, E2B_02658460, E2B_02659856, E2B_02671562.Organization: Health Canada
January 2020
Req # A-2019-001455
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 19-119896-720, Vaping prevention advertising and influencer outreach during the 2019 federal election.Organization: Health Canada
January 2020
Req # A-2019-001457
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 19-119559-698, Monthly Cannabis IT System Status Report.Organization: Health Canada
January 2020
Req # A-2019-001479
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 19-119896-720, Vaping prevention advertising and influencer outreach during the 2019 federal election.Organization: Health Canada
January 2020